Teva Pharmaceuticals

@TevaUSA ↗

Deleted No

Hibernated No

Last Checked April 3, 2023

Created

Wed Nov 09 15:05:04 +0000 2022

Likes

Retweets

Source

Twitter Web App

View Raw Data

JSON Data

View on Twitter

Likely Available

Teva Pharmaceuticals @TevaUSA

Cory Wohlbach is back onstage today at #GRxBiosims breaking down the Biosimilar User Fee Act (BsUFA III), recently reauthorized by Congress. Cory is shedding light on FDA’s new regulatory science pilot program aimed at advancing biosimilar products. https://t.co/AGjuOBAWi3 — PolitiTweet.org

Posted Nov. 9, 2022

Preceded By

Teva Pharmaceuticals @TevaUSA

Christine Baeder, SVP, COO for US Generics at Teva and AAM Vice Chair shares a recap of the exciting happenings at #GRxBiosims 2022. She sat down with AAM to discuss the regulatory environment and the need for collaboration to pave the way for complex generics and biosimilars. — PolitiTweet.org

"It's an exciting time to gather at GRx+Biosims 2022. No one mind can solve our problems, it really takes people co… https://t.co/XKoTv2Oh8U

Posted Nov. 9, 2022

Followed By

Teva Pharmaceuticals @TevaUSA

The passage of #BsUFA III showcases forward-thinking goals aimed at bringing biosimilars to market faster, improving patient access, and delivering savings across the system – Teva’s Cory Wohlbach states, live @AccessibleMeds #GRxBiosims https://t.co/e6GSbDpkR6 — PolitiTweet.org

Posted Nov. 9, 2022